Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Kyorin Pharmaceutical Co's annualizedNet Income for the quarter that ended in Mar. 2026 was $-16.9 Mil. Kyorin Pharmaceutical Co's average total tangible assets for the quarter that ended in Mar. 2026 was $1,212.4 Mil. Therefore, Kyorin Pharmaceutical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -1.40%.
The historical rank and industry rank for Kyorin Pharmaceutical Co's Return-on-Tangible-Asset or its related term are showing as below:
KYRNF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.81 Med: 3.52 Max: 5.03
Current: 1.84
During the past 13 years, Kyorin Pharmaceutical Co's highest Return-on-Tangible-Asset was 5.03%. The lowest was 1.81%. And the median was 3.52%.
KYRNF's Return-on-Tangible-Asset is ranked worse than 56% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.13
vs KYRNF: 1.84
Kyorin Pharmaceutical Co (OTCPK:KYRNF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Kyorin Pharmaceutical Co Return-on-Tangible-Asset Related Terms
Kyorin Pharmaceutical Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Kyorin Pharmaceutical Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyorin Pharmaceutical Co Return-on-Tangible-Asset Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyorin Pharmaceutical Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Kyorin Pharmaceutical Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -1.40% mean?
Kyorin Pharmaceutical Co (KYRNF) has a Return-on-Tangible-Asset of -1.40% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Kyorin Pharmaceutical Co and its competitors. Over the past decade, Kyorin Pharmaceutical Co's Return-on-Tangible-Asset has ranged from 1.81 to 5.03. According to the industry distribution chart, Kyorin Pharmaceutical Co ranks #565 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 56%.
Is Kyorin Pharmaceutical Co's Return-on-Tangible-Asset too high?
Kyorin Pharmaceutical Co's current Return-on-Tangible-Asset is -1.40%. Over the past 10 years, this metric has ranged from a low of 1.81 to a high of 5.03. Based on the distribution chart, Kyorin Pharmaceutical Co ranks #565 out of 1009 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Kyorin Pharmaceutical Co has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Kyorin Pharmaceutical Co's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kyorin Pharmaceutical Co ranks #565 out of 1009 companies for Return-on-Tangible-Asset. This places Kyorin Pharmaceutical Co in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.13. Historically, Kyorin Pharmaceutical Co's own Return-on-Tangible-Asset has ranged from 1.81 to 5.03 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.13, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Kyorin Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyorin Pharmaceutical Co's current Return-on-Tangible-Asset is -1.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyorin Pharmaceutical Co stock overvalued right now?
Kyorin Pharmaceutical Co (KYRNF) has a current Return-on-Tangible-Asset of -1.40%. The stock's GF Value™ is $13.86, compared to a current price of $10.31 — trading 25.6% below its estimated fair value. The current Return-on-Tangible-Asset is -1.40%. Kyorin Pharmaceutical Co's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Kyorin Pharmaceutical Co (KYRNF), the current Return-on-Tangible-Asset is -1.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyorin Pharmaceutical Co (KYRNF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued.
The current stock price of $10.31 is trading 25.6% below its estimated GF Value™ of $13.86.
Key valuation signals for KYRNF:
Return-on-Tangible-Asset: -1.40%
GF Value™: $13.86 vs. price of $10.31 (25.6% below fair value)
No single metric tells the full story. See the KYRNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
74GF Score
Get the complete analysis for KYRNF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYRNF has been successfully added to your 
